Company intelligence / Profile preview
AB2 Bio Ltd.
Lausanne, Vaud, Switzerlandab2bio.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
01
Overview
AB2 Bio has completed Phase 3 trials for Tadekinig alfa in North America and Europe and is preparing for submission of a Biologics License Application (BLA) in the U.S. The drug has received Orphan Drug Designation, Breakthrough Therapy Designation, and Rare Pediatric Disease Designation in the U.S., and Orphan Drug Designation in Europe.
- Therapeutic areas
- ImmunologyRare DiseasesRheumatology
- Modalities
- Recombinant protein (Tadekinig alfa is a recombinant human IL-18 binding protein)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Nippon Shinyaku (licensing agreement for U.S. commercialization of Tadekinig alfa)WuXi Biologics (manufacturing collaboration)
Beyond the preview
Go deeper on AB2 Bio Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AB2 Bio Ltd..